EUROPE PLATELET RICH PLASMA MARKET ANALYSIS

Europe Platelet Rich Plasma MarketSize and Trends

Europe Platelet Rich Plasma Marketis estimated to be valued at US$ 110.4 Million in 2023, exhibiting a CAGR of 15.6 % during the forecast period (2023-2030).

Figure 1. Europe Platelet Rich Plasma Market Share (%), By Product Type, 2023

Europe Platelet Rich Plasma Market– Drivers

Rising Use of Platelet-Rich Plasma in Various Therapeutic & Clinical Areas

The increasing use of Platelet-Rich Plasma in various therapeutic and clinical areas, is expected to grow the global platelet rich plasma market over the forecast period. For instance, in June 2021, according to the report published in the National Center for Biotechnology Information, platelet-rich plasma (PRP) is becoming more popular as a non-operative treatment option for a broad spectrum of medical disorders. Also, PRP is widely used in orthopedic and sports medicine to relieve pain through the natural promotion of healing in musculoskeletal diseases such as tendonitis, arthritis, ligament sprains, and tears.

Figure 2. Europe Platelet Rich Plasma Market Value (US$ Million), By Country, 2023

Europe Platelet Rich Plasma Market- Segmentation

Europe Platelet Rich Plasma market is segmented into PRP type, origin, application and country.

Based on PRP type, the market is segmented into Pure-PRP, Leukocyte-Rich PRP, Pure Platelet Rich Fibrin, Others. Out of which, the Pure-PRP segment is expected to hold a dominant position in the Europe Platelet Rich Plasma market during the forecast period, owing to increasing use of Pure-PRP.

Based on Origin, the market is segmented into Autologous, Allogeneic/Homologues. Out of which, the Autologous segment is expected to hold a dominant position in the Europe Platelet Rich Plasma market during the forecast period, due to increasing use of autologous platelet rich plama products.

Based on Application, the market is segmented into Orthopaedics, Cosmetic Surgery and Dermatology, Neurosurgery, Cardiothoracic Surgery, General Surgery, Urology, Others. Out of which, the Orthopaedics segment is expected to hold a dominant position in the Europe Platelet Rich Plasma market during the forecast period, due to increasing use of platelet rich plama products for orthopedics.

Based on Country, the market is segmented into U.K., Germany, France, Italy, Spain, Russia, Rest of Europe. Out of which, the U.K. is expected to dominate the market over the forecast period, owing to increasing inorganic growth strategies such as collaboration by key players in the region.

Among all segmentation, the application segment has the highest potential due increasing cosmetic procedures worldwide, which is expected to drive the growth of the segment in the global market over the forecast period. For instance, in 2021, according to Plastic Surgery Statistics Report: 2020, about 16.6 million procedures were carried out, and 13.2 million cosmetic minimally-invasive procedures were carried out.

Europe Platelet Rich Plasma Market- Market Trends

Increasing Research and Development Activities By Key Market Players

Increasing research and development activities for PRP by key market players, in order to expand their product portfolio is expected to drive the market growth over the forecast period. For instance, in June 2022, a research article published in the Journal of Skin and Steam Cells, where researchers found that under sterile conditions, platelet rich plasma preparation and administration protocol reduced the prevalence of further contamination and complications associated with it. The occurrence of infection after injection was zero, even in patients with hemophilia. When carried out under controlled circumstances, platelet rich plasma therapy is effective for treating a wide range of etiologies and involves both intra-articular and soft tissue operations with no danger of infection.

Europe Platelet Rich Plasma Market - Country Analysis

Among countries, the U.K. is estimated to hold a dominant position in the Europe platelet rich plasma market over the forecast period, due to increasing research and development activities. For instance, on June 5, 2022, a research article published in the Journal of Skin and Steam Cells, where researchers found that under sterile conditions, platelet rich plasma preparation and administration protocol reduced the prevalence of further contamination and complications associated with it. The occurrence of infection after injection was zero, even in patients with hemophilia. When carried out under controlled circumstances, platelet rich plasma therapy is effective for treating a wide range of etiologies and involves both intra-articular and soft tissue operations with no danger of infection.